Two federal announcements in October 2026 changed the self-disclosure conversation for healthcare businesses. On October 15, DOJ and HHS-OIG announced coordinated handling of certain voluntary criminal health care fraud disclosures. On October 22, DOJ’s Civil Division and HHS announced a separate six-month pilot for eligible civil False Claims Act matters. The programs are related but not interchangeable. For a separate but potentially related procedural question, read what to do when an agency contacts a provider about a healthcare fraud referral.
October 15: coordinated criminal disclosure
The Justice Department announced that companies seeking the benefits of both the Department’s Corporate Enforcement and Voluntary Self-Disclosure Policy and HHS-OIG’s Health Care Fraud Self-Disclosure Protocol for potential criminal healthcare conduct can disclose to the Fraud Division’s Health Care Fraud Section, without a duplicate direct HHS-OIG submission in the specified circumstances.
The agencies cautioned that disclosure only to HHS-OIG generally does not count as voluntary self-disclosure to DOJ for Corporate Enforcement Policy declination purposes. The choice of forum and timing should follow a privileged legal assessment of potential criminal, civil, and administrative exposure.
October 22: a six-month civil False Claims Act pilot
The DOJ Civil Division announced a Healthcare False Claims Act Self-Disclosure Pilot Program for eligible civil misconduct, with submissions accepted through April 22, 2027. DOJ describes a process requiring detailed disclosure, meaningful remediation, document production, and a financial repayment multiplier of 1.25 to 1.6, with the multiplier depending on stated factors.
The announced benefit is a coordinated civil release under the federal FCA and certain HHS authorities for qualifying resolutions. The existence of a pilot does not mean every claim discrepancy warrants a pilot submission or that an organization may self-select its multiplier.
Classify the concern before contacting the government
A billing mistake, an identified overpayment, an alleged kickback arrangement, and an intentional false billing scheme raise different legal questions. An internal investigation should test what happened, who knew, what claims were affected, whether remuneration or exclusion issues exist, and whether any prompt reporting or repayment obligations run independently.
If potentially criminal conduct is implicated, the October 22 announcement directs attention to the Fraud Division route. Organizations seeking civil resolution may need additional information. The public guidance itself emphasizes separating the criminal and civil protocols instead of treating them as two identical portals.
Preserve facts and control messaging
Preserve claims data, vendor and marketing contracts, communications, compliance concerns, payment flows, remedial actions and relevant legal advice under a defensible investigation plan. Avoid asking employees to rewrite historical records or sending incomplete allegations without a defined strategy.
Self-disclosure may confer important benefits, but it can also expose additional facts, personnel, and business relationships. A company should obtain counsel before characterizing conduct or making a submission.
The October 15 policy addresses potential criminal misconduct
DOJ’s National Fraud Enforcement Division and HHS-OIG announced coordinated healthcare self-disclosure guidance on October 15, 2026. For a company seeking voluntary self-disclosure credit for potentially criminal healthcare fraud, the guidance directs disclosure to DOJ’s Fraud Division rather than assuming a submission to HHS-OIG alone will produce the same result. The policy is intended to coordinate treatment under DOJ’s Corporate Enforcement Policy and HHS-OIG’s Self-Disclosure Protocol. That coordination is not a blanket promise of immunity or a substitute for meeting eligibility and cooperation requirements. A provider should identify whether the evidence suggests intentional false claims, unlawful remuneration, exclusion-related misconduct, erroneous billing or a different violation before deciding which agency’s procedure applies.
The October 22 civil pilot has defined limits
DOJ’s Civil Division and HHS launched a six-month Healthcare False Claims Act Self-Disclosure Pilot Program on October 22, 2026, accepting submissions through April 22, 2027. The program concerns potential civil False Claims Act violations and offers a path to coordinated civil resolution for qualifying companies. DOJ describes detailed disclosure and documentation requirements, remedial action and a financial repayment using a multiplier that varies between 1.25 and 1.6. The specific outcome depends on the program and facts, including timeliness and leadership involvement. Incomplete or late submissions will not be reviewed under the announced pilot. Companies should not treat the program as an automatic discount or as a way to release unrelated private or state claims.
An internal investigation must precede a defensible disclosure
When a compliance team finds questionable billing, preserve claim data, contracts, communications, clinical records and the original allegation before deciding whether disclosure is appropriate. Establish whether the issue is isolated, repeated or linked to the same operational cause. Assess the applicable Medicare overpayment rules and any other repayment deadlines separately from self-disclosure incentives. A careless report that labels every disputed medical-necessity claim fraudulent can create unnecessary consequences; an incomplete presentation that omits known evidence may undermine cooperation credit. Counsel should manage scope, conflicts, privilege and the distinction between factual investigation and conclusions. Quantify what is actually known, identify uncertainties and document remedial measures that have genuinely occurred.
Coordinate civil, criminal and administrative pathways
An arrangement involving referral compensation, exclusion, falsified clinical records or repeated false claims can raise questions under more than one statute. The October 15 coordinated criminal pathway and the October 22 civil pilot interact, but they are not interchangeable. DOJ’s announcement explains that a company making a proper criminal disclosure does not necessarily need a duplicative civil pilot submission; additional information may be requested when a coordinated civil release is sought. HHS-OIG’s protocol also remains relevant for administrative consequences. Before contacting any agency, prepare a decision memorandum identifying potential exposure, required disclosure route, monetary analysis, remediation and who may lawfully represent the entity and individuals. The policy should encourage prompt accuracy, not rushed assumptions.
Sources and authorities
- DOJ, October 15, 2026 Criminal Health Care Self-Disclosure Coordination
- DOJ, October 22, 2026 Civil FCA Self-Disclosure Pilot
- HHS-OIG, Health Care Fraud Self-Disclosure
Facing an investigation or legal question? Discuss Healthcare Investigation Counsel or send a short nonconfidential inquiry. BOLO Health Law is based in New Jersey; counsel availability in other jurisdictions depends on applicable rules. This article offers general information only and does not establish an attorney-client relationship.